Related Experiment Videos
TGF-beta1 neutralizing antibodies decrease the fibrotic effects of ischemic priapism
O Sanli1, A Armagan, E Kandirali
1Istanbul Faculty of Medicine, University of Istanbul, Istanbul, Turkey.
International Journal of Impotence Research
|July 31, 2004
Summary
Transforming growth factor beta 1 (TGF-beta1) antibodies may prevent priapism-induced fibrosis. This study found TGF-beta1 antibodies reduced fibrosis in a rat model, particularly for shorter priapism durations.
Area of Science:
- Urology
- Andrology
- Fibrosis Research
Background:
- Priapism can lead to penile fibrosis and erectile dysfunction.
- Transforming growth factor beta 1 (TGF-beta1) is implicated in fibrotic processes.
Purpose of the Study:
- To investigate the efficacy of TGF-beta1 antibodies in preventing priapism-induced fibrosis.
- To evaluate the impact of TGF-beta1 inhibition on erectile function after induced priapism in rats.
Main Methods:
- Priapism was induced in Sprague-Dawley rats using a vacuum device and rubber band.
- TGF-beta1 antibodies were administered intracavernosally 1 hour after priapism induction.
- Erectile function was assessed via cavernous nerve stimulation and pressure measurements after 8 weeks.
Main Results:
- Rats treated with TGF-beta1 antibodies showed significantly less fibrosis compared to untreated groups.
- Intracavernous pressure (ICP) and ICP/BP ratios were higher in the group with shorter priapism duration (6 hours) treated with antibodies.
- Histopathological examination confirmed reduced fibrotic changes in antibody-treated rats.
Conclusions:
- TGF-beta1 antibodies effectively antagonize the fibrotic effects of priapism.
- Early administration of TGF-beta1 antibodies shows promise in mitigating priapism-related penile fibrosis, especially in cases of shorter duration.